WuXi Biologics Commences Construction on Microbial Production Base in Chengdu
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...
Sihuan Pharma’s Xuanyuening Granted New Indication Review in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases
US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...
Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion
Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...
ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...
Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...
Suzhou Sinus Medtech Wins FDA Breakthrough Designation for oHCM Ablation System
Suzhou Sinus Medical Technologies Co., Ltd., a China-based medical device innovator, announced that its in-house...
Novartis’ PSMAddition Trial Yields Positive Results for Pluvicto in mHSPC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced the interim results from its Phase III PSMAddition...
Innovent Biologics’ Xinbiyue Approved for Macau Market
China-based Innovent Biologics Inc. (HKG: 1801) announced that it has received market approval from the...
Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...
Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market
US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...
FDA Approves Merck’s Enflonsia for Infant RSV Protection
The US Food and Drug Administration (FDA) granted approval to Merck, Sharp & Dohme’s (MSD;...
Sino Biopharmaceutical Gains CDE Approval for TQC3721 COPD Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...
Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs
China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced a strategic partnership with US-headquartered Medicovestor, Inc. to...
Huahai Pharma Receives FDA Warning Letter After Inspection
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...
Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) released its Q1 2025 financial report, showing a...
Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology
China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...
CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine
China Isotope & Radiation Corporation (CIRC; HKG: 1763) and Hong Kong-based Qianlong International Holdings Ltd....
AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) announced that the European Commission (EC) has approved its...